Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Klotz

Showing results (1-10 of 343) with videos related to

Pageof 35
Sort By:
Translational Andrology and Urology|January 28, 2016
Active surveillance and focal therapy for low-intermediate risk prostate cancerLaurence Klotz
Lancet (London, England)|December 14, 2002
ReactionsLaurence Klotz
World Journal of Urology|January 25, 2021
Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancerLaurence Klotz
JAMA Oncology|November 10, 2022
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate CancerLaurence Klotz
Current Treatment Options in Oncology|August 15, 2006
Active surveillance versus radical treatment for favorable-risk localized prostate cancerLaurence Klotz
European Urology|December 8, 2004
Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancerLaurence Klotz
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 15, 2021
Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questionsLaurence Klotz
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Point: active surveillance for favorable risk prostate cancerLaurence Klotz
Nature Clinical Practice. Urology|November 29, 2007
Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed interventionLaurence Klotz
Urologic Oncology|January 18, 2006
Active surveillance with selective delayed intervention for favorable risk prostate cancerLaurence Klotz
Pageof 35

Showing results (1-10 of 343) with videos related to

Sort By:
Pageof 35
Translational Andrology and Urology|January 28, 2016
Active surveillance and focal therapy for low-intermediate risk prostate cancerLaurence Klotz
Lancet (London, England)|December 14, 2002
ReactionsLaurence Klotz
World Journal of Urology|January 25, 2021
Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancerLaurence Klotz
JAMA Oncology|November 10, 2022
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate CancerLaurence Klotz
Current Treatment Options in Oncology|August 15, 2006
Active surveillance versus radical treatment for favorable-risk localized prostate cancerLaurence Klotz
European Urology|December 8, 2004
Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancerLaurence Klotz
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 15, 2021
Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questionsLaurence Klotz
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Point: active surveillance for favorable risk prostate cancerLaurence Klotz
Nature Clinical Practice. Urology|November 29, 2007
Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed interventionLaurence Klotz
Urologic Oncology|January 18, 2006
Active surveillance with selective delayed intervention for favorable risk prostate cancerLaurence Klotz
Pageof 35